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INTRODUCTION
Drug addictions to psychoactive substances are disorders with a complex bio-psycho-social genesis. They are characterised with chronic relapses of the disorder. Just like all chronic conditions, their treatment is a long-term process, which may require prolonged and repeated episodes of treatment in order to achieve a stable and sustained remission as well as a lasting recovery. The most commonly used drug for the treatment of opioid dependency in Bulgaria is methadone. It is a synthetic, long-acting agonist of the μ-receptors. It has morphine-like effects such as analgesia, euphoria, sedation, respiratory depression, miosis, bradycardia and physical dependence. The drug was developed in Germany in 1937 by Max Bockmühl and Gustav Ehrhart who worked for the German chemical conglomerate IG Farberindustrie. led to multiple fatalities. Many deaths of young people were registered in England and Germany from 1940 to 1950 as a result of taking cough medicine containing methadone. 1 In the modern history of medicine and the correct use of opioids, methadone is mainly used as a tool in maintenance therapy in patients with opioid dependence and less frequently as an analgesic. Chronic methadone maintenance therapy started in the early 1960s in an attempt to counter the emerging epidemic of heroin use and abuse after World War II. In New York, the intravenous use of heroin grew dramatically and by the end of the 1960s it was widely used. 2 From 1950 to 1961, the death rate from intravenous heroin abuse increased from 7.2 per 10000 to 35.8 per 10000 deaths, and 75% of the deceased were between 15-35 years of age. During this period the mortality rate of i.v. heroin abuse became the major cause of mortality in New York amongst the younger population. The mean age of heroin related deaths for both sexes was 29 years. In 1989 there were about 1300-1400 registered drug addicts in the National Register of Republic of Bulgaria, with their actual number until 1990 not exceeding 600-800 people. The fi gure of 1300-1400 people included all people from the beginning of 1980, using medical opiates such as morphine and Lidol. The peak of drug use was observed after the democratic changes in 1989 and the subsequent liberalisation processes, combined with the destruction of the repressive control apparatus of the country. The reasons for the lack of a drug market in the country before 1990 can only be speculated and could be due to the success of totalitarian control agreements between the Bulgarian secret services and organized crime. 3 In summarized data from studies in the period from 2010 to 2012 a total of about 560-570 000 Bulgarian citizens, in the age range 15 to 64 years, had used some narcotic substance at least once in their lives. Heroin has been the narcotic drug most associated with the problematic use of drugs in Bulgaria for the last 20 years. A survey from 2010 was used to assess 31 316 problematic drug substance users in Bulgaria. 4 The treatment of drug addictions in Bulgaria is based on the principles adopted in the medical standard "Psychiatry". The treatment of addicted patients goes through three main phases: 1. Introduction phase -stabilization of the patient and determining the sustainable supporting individual daily dose of medicine.
2. Phase of rehabilitation and supportive treatment. 3. The fi nal phase -drawing up an individual plan for the completion of treatment and exit from the program, determining the rate of dose reduction and monitoring the medical and psychological condition of the patient. Detoxifi cation is both short and long term. It is used if it is requested by the patient indicated following a medical team assessment or, if necessary, because of treatment discontinuation for other reasons.
Following the implementation of the National Programme for Prevention, Treatment and Rehabilitation of Drug Addiction in the Republic of Bulgaria, a series of methadone maintenance treatment (MMT) programs with opiate agonists and agonists acting as antagonists were launched between 2001 and 2005. 5 Currently, Bulgaria has thirty registered programs. The total number of patients participating in these groups is 4692. Of these, 4292 receive the methadone treatment, 232 undergo treatment with Substitol and 168 are treated with buprenorphine. The estimation of the average daily dose of methadone is a complex task, which is individually determined for each patient. The average daily dose usually ranges between 80-120 mg / day. This amount of methadone should be adequate for: 1. Overcoming the craving for narcotics. 2. Suppression of the opioid withdrawal syndrome for a period of 24-36 hours. 3. Blocking the effect of the administered heroin. 4. Development of tolerance towards euphoria, sedation or other narcotic effects of methadone, which will have a negative impact on the emotional status, perception and capacity of the patient. 5. Developing a tolerance to the analgesic effect of methadone.
It should be noted that some patients need higher doses of methadone. On the other hand, in some patients, the required effects are achieved at lower doses of 60-80 mg / day. The study of GAO (Government Accounting Offi ce) on the effectiveness of methadone programs in the US shows that the minimum effective dose of methadone is 60 mg / day. 6 A patient adequately maintained on methadone, who is not abusing heroin or other drugs or alcohol, experiences normal emotions and sensitivity for acute and chronic pain. The required methadone dose is determined by the quality and duration of use of heroin, as well as its route of administration.
Chronic methadone maintenance therapy has proven effective in reducing the incidence of transmissible infections such as human immunodefi ciency virus (HIV) hepatitis B virus (HBV) and hepatitis C virus (HCV) among intravenous drug users, improving the effectiveness of anti-retroviral treatment for HIV / AIDS and treatment of chronic viral hepatitis. 7 A reduction in crime rates 8 and use of illicit drugs 9 is found in patients undergoing chronic treatment with methadone, as well as improved social integration and family relationships. It has been shown that chronic maintenance treatment with methadone has a positive effect on the quality of life making it better than that at baseline. [10] [11] [12] HCV is a life-threatening disease and as such it has a great impact on society. 13 The purpose of this study was to analyze and compare the infl uence of the length and the average daily dose for chronic use of methadone on the quality of life.
MATERIALS AND METHODS
This study uses a prospective, observational, crosssectional questionnaire-based study method. The questionnaire used in the study is standardized and validated for use in the Bulgarian language: SF 36 v.2, quality of life, which assesses the quality of life in eight different components: physical functioning (PF), role-physical (RP), bodily pain (BP), general health (GH ), vitality (VT), social functioning (SF), role-emotional (RE), mental health (MH). It provides a summarized evaluation both for physical (PCS) and mental components (MCS). 14, 15 The assessment of each component is on a scale of 0 to 100, with scores of 100 indicating the best condition. The evaluation system is based upon a representative sample of the population and the questionnaire can be used to assess the physical and mental status of the participants in relation to the general population -norm-based scores (NBS). The total number of participants was 100 people divided into two groups -74 patients undergoing chronic treatment with methadone in the patients' group and 24 healthy volunteers in the control group. There were no signifi cant differences in age and sex between the groups. A total of fi ve methadone maintenance treatment programs with opiate agonists and agonists-antagonists at four big cities in Bulgaria -Sofi a, Plovdiv, Pazardjik, Stara Zagora, were included in the study. Patient group was classified as three subgroups based on the mean and SD of the following three factors: dose, duration of treatment, and exposure to heroin before fi rst methadone treatment. The low subgroup had one of the three factors below one SD of the mean (i.e., < mean-SD); medium subgroup had one of the three factors between one SD (i.e., mean±SD); high subgroup had one of the three factors above one SD of the mean (i.e., > mean+SD). The age range of the patients was between 18 and 40 years. Exclusion criteria were accompanying mental disorders and substance abuse in the past three months. Prevalence of HCV was taken in consideration as marking the status from medical documentation available in the methadone programs for each patient.
For the purposes of comparison analyses we used 24 healthy volunteers as a control group. Criteria for inclusion in the control group were no history of drug abuse and age range from 18 to 40 years. Exclusion criteria were accompanying physical or mental disorders. Control and patients' group were also matched by BMI and there was no difference between the groups by this criterion. Comparisons of survey results were performed between patients and healthy controls also between subgroups, divided by factors dose, duration of exposure to methadone and duration of exposure to heroin prior initiation of treatment of methadone in the patients' group. The survey form in Bulgarian language is offi cially translated and validated and the software for processing the results was presented courtesy of OptumTM, which possesses the right to distribute and license the survey. 16 For statistical analyses we used SPSS Inc., IBM SPSS Statistics v. 21.0. The statistical methods used in the investigations were descriptive statistics, independent samples t-test, Fisher's exact test ANOVA, post-hoc analysis.
RESULTS
The mean daily dose of methadone used for maintenance treatment of the patients was 9.8 (± 4.0) ml/ daily or 98 mg/daily. The mean duration of treatment was 33.68 (± 24.25) months and the mean duration of exposition to heroin before starting treatment with methadone was 6.54 (± 3.4) years. Numbers of patients of the 3 subgroups by dose, duration of treatment and exposure to heroin before initiating treatment with methadone in patients' group are presented in Table 1 .
The mean score of all the components of the survey is presented in Table 2 .
Comparisons between the patients' group and control group showed that there were signifi cant differences in all of the components of the survey (P<0.05). The patients group showed signifi cantly lower results in all eight domains as well as the PCS and MCS (Fig. 1.) In-group analyses in the patients' group were made by doing comparison analyses of the defi ned subgroups by dose, duration of treatment and exposure to heroin prior treatment. No signifi cant differences were found in any of the components of the survey between the subgroups.
51.32% of patients had a history of HCV. Compared by presence of HCV no signifi cant differences were found by any of the domains of the survey between two groups.
DISCUSSION
This study evaluated the effect of MMT on patients from 5 programs in subjective function and well-being. The key results indicated that patients on MMT experienced a marked decrease in scores on all scales, as well as the PCS and MCS of the SF-36-survey. It must be taken in consideration that co-occurring psychiatric disorders are among the diffi culties faced by patients with MMT and negatively impact quality of life. 17 People undergoing chronic MMT are in a young age with much co-morbidity 18 infected with HBV, HBC, HIV 19 . It is well-known that the majority of patients undergoing chronic MMT experience problems with erectile function, endocrine disturbances and reproduction diffi culties. [20] [21] [22] In the attempt to solve problems of the opiate abusers multidisciplinary approach should be used which is a guarantee of success and the key to improving the quality of life of target population. 
